Clinical Trial Detail

NCT ID NCT03554109
Title QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors NantKwest, Inc.
Indications

triple-receptor negative breast cancer

Therapies

NANT triple negative breast cancer vaccine combination

Paclitaxel + Doxorubicin + Cyclophosphamide

Age Groups: adult senior

Additional content available in CKB BOOST